Can-Fite BioPharma (NYSE:CANF) Stock Rating Lowered by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Wednesday.

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Trading Down 2.0 %

NYSE CANF opened at $1.97 on Wednesday. The company has a market cap of $6.97 million, a PE ratio of -1.13 and a beta of 1.39. Can-Fite BioPharma has a 12 month low of $1.87 and a 12 month high of $4.69. The stock has a 50 day moving average of $2.23 and a 200-day moving average of $2.52.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC lifted its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 518,853 shares of the company’s stock after purchasing an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 as of its most recent SEC filing. Institutional investors and hedge funds own 21.00% of the company’s stock.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.